Biomea Fusion Announces Poster Presentation Of Phase 1 Results For BMF-650, Its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, At Obesityweek® 2026
Presentation Details
Title: First-In-Human Study Results for BMF-650 a Small Molecule Oral GLP-1 Receptor Agonist
Session: Obesity-Related Complications & Multimorbidity
Poster Number: Poster 828
Presenter: Thorsten A. Kirschberg, Ph.D.
Session Date/Time: Monday, November 16, 2026, at 2:30 p.m. – 3:30 p.m. ET
After the conference concludes, the poster will be available in the Investors & Media section of the company's website.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world's population. Biomea's mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity and related conditions. We aim to cure.
Visit us at and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment